The independent Advisory Team is comprised of scientific experts in the focus areas of the aiForward program.
The members of the Advisory Team review the applications and evaluate the scientific validity of the project proposals. The Advisory Team also provides expert insights and guidance on research projects which are selected for the program.
Joseph Geradts, MD, MA
Dr. Geradts is a Clinical Professor and Director of the Multi-Scale Translational Research Core in City of Hope National Medical Center in Duarte, CA, United States. Dr. Geradts is a board-certified specialist in anatomical pathology and widely accomplished as a cancer researcher and clinician. Read More
Dr. Geradts’ research interests include intratumoural heterogeneity, molecular pathogenesis of breast cancer, and biomarkers of breast cancer progression. He has collaborated on numerous cancer research projects with investigators from a wide range of disciplines. In addition, Dr. Geradts has conducted his own extramurally funded breast cancer research program, resulting in almost 150 peer-reviewed scientific publications so far. Recently he has been involved in and initiated several studies that utilize deep learning algorithms for the development of novel prognostic and predictive breast cancer models.
Fredric Manfredsson PhD
Dr. Manfredsson is an Assistant Professor of Translational Science and Molecular Medicine at Michigan State University College of Human Medicine in Grand Rapids, MI, United States. Dr. Manfredsson received his undergraduate training in microbiology and virology at Arizona State University and his PhD in Biomedical Sciences-Neuroscience from the University of Florida. Read More
Juha Kononen MD, PhD
Dr. Kononen is a board-certified oncologist, currently leading the Department of Oncology in Central Finland Central Hospital in Jyväskylä, Finland. Since 2019, he has also acted as head of personalized oncology in Docrates Cancer Center, Helsinki, Finland. Read More
During his research career in Finland, Switzerland, and United States, Dr. Kononen specialized in translational cancer research in which he utilized his own invention: tissue microarray technology for high-throughput molecular profiling of tumour specimens. Since then, tissue microarrays have revolutionized pathology research and are currently used in over 1,000 laboratories worldwide to study gene and protein expression from cellular specimens.